Clinical Trial Update: BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 trial comparing risankizumab to adalimumab in moderate-to-severe chronic plaque psoriasis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• ADALIMUMAB (ADALIMUMAB-AATY)
• Risankizumab (risankizumab)

Snippet

Sponsor: AbbVie | Conditions: Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2019-05-28